Gel Column Agglutination Test system Market - Global Forecast 2025-2032

The gel column agglutination test system market is gaining traction as healthcare leaders modernize blood transfusion practices. By facilitating safer, more standardized diagnostics, these systems support critical hospital and laboratory operations while streamlining regulatory compliance in transfusion medicine.

Market Snapshot: Gel Column Agglutination Test System Market

The gel column agglutination test system market grew from USD 3.50 billion in 2024 to USD 3.73 billion in 2025, with an anticipated CAGR of 6.73%. Forecasts suggest the market will reach USD 5.89 billion by 2032.

Scope & Segmentation of the Gel Column Agglutination Test System Market

This comprehensive report explores how advances in gel column agglutination systems are shaping the future of transfusion diagnostics globally. Key segments capturing the scope and diversity of the market include:

• Test Types: Antibody screening, crossmatch methods, and both forward and reverse typing as well as identification protocols, all designed to enhance transfusion compatibility and lower clinical risk.
• End Users: Blood banks, diagnostic laboratories, hospitals, and research institutes—each sector requires tailored solutions for workflow, compliance, and technology integration in both public and private healthcare.
• Product Types: Consumables such as gel columns and reagent cards, together with automated and semi-automated instruments, support rigorous accuracy, flexible platform options, and standardization of laboratory processes.
• Applications: Diagnostics across blood transfusion safety, disease screening—including both autoimmune and infectious markers—and research-based testing, covering both routine operations and specialized clinical needs.
• Sample Types: Testing protocols accommodate plasma, cryoprecipitate, fresh frozen plasma, red cells (packed or washed), and whole blood from citrated or EDTA tubes, ensuring compatibility and reliability across sample sources.
• Blood Group Systems: Includes ABO, Duffy, Kell, Kidd, MNS, and Rh blood group systems, forming the scientific basis for immunohematology practice and patient safety.
• Regions Covered: The Americas, Europe, Middle East, Africa, and Asia-Pacific, with each region characterized by specific adoption patterns and regulatory environments, reflecting various stages of market maturity and infrastructural investment.
• Key Companies Profiled: Ortho Clinical Diagnostics Holdings plc, Bio-Rad Laboratories, Inc., Grifols, S.A., Thermo Fisher Scientific Inc., Danaher Corporation, Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Immucor, Inc., Diagast, and Abacus Diagnostica Ltd., all of which shape the industry through technological innovation and strategic collaboration.

Key Takeaways for Senior Decision-Makers

• Automation and advanced imaging technology drive consistency and increase throughput, optimizing immunohematology workflows for large-scale healthcare systems and networks.
• Innovations in gel matrices and reagent formulations enable detection of complex blood phenotypes and rare antigens, allowing for highly targeted research and improving diagnostic precision.
• Regional strategic priorities diverge: mature healthcare systems invest in fully digital solutions, while growing markets favor modular, scalable platforms to align with available resources and changing patient needs.
• Collaboration spanning equipment, reagent, and IT partners facilitates the deployment of integrated, intelligent laboratory platforms that unify workflow management and data interoperability.
• Comprehensive service integration—including training, digital result reporting, and external quality assurance—builds stronger user engagement, maximizes operational value, and ensures smooth process transitions for healthcare providers.

Impact of 2025 US Tariff Policies on Global Supply Chains

Recent changes to US tariff policies affecting imported reagents and consumables are reshaping sourcing strategies. Manufacturers are shifting toward regional and local production to control costs and ensure a stable supply of diagnostic materials. Healthcare providers, including hospitals and blood banks, are updating procurement models, negotiating new contracts, and intensifying coordination with suppliers. Ongoing industry and policy engagement supports stable access to critical materials and reinforces diagnostics network resilience.

Methodology & Data Sources

The findings in this report are based on primary interviews with transfusion specialists, laboratory managers, and procurement executives. Supplementary sources include peer-reviewed research, regulatory filings, and industry analyses. Rigorous data validation underpins actionable, executive-level insights.

Why This Report Matters

• Comprehensive analysis enables leaders to benchmark performance and make technology investments targeted to specific market dynamics.
• Segment-led insights support informed partnerships, encourage innovation, and drive portfolio expansion in both mature and developing healthcare markets.
• Detailed supply chain perspectives guide risk management, supporting the ongoing resilience and continuity of essential diagnostic processes.

Conclusion

Sustained success in the gel column agglutination test system market depends on strategic innovation, enhanced workflow efficiency, and collaborative partnerships. Integrating advanced technology with coordinated approaches positions organizations for ongoing leadership.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.